Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10471334 | 0.74 | CYP2A6 (0.38) | ALDH1A1HPGDSMN1; SMN2LMNAMEN1 | |
| SCHEMBL7046450 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EMAPTMAPK1 | |
| SCHEMBL7046728 | 0.68 | LTA4H (0.39) | ALDH1A1HPGDRAB9ALMNAKMT2A | |
| SCHEMBL3619254 | 0.66 | ALDH1A1 (0.44) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 | |
| SCHEMBL617580 | 0.61 | ALDH1A1 (0.53) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 | |
| Biphenyl SCHEMBL28042419 | 0.61 | ALDH1A1 (0.71) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 | |
| SCHEMBL6750319 | 0.61 | KDM4E (0.32) | KDM4EMAPTMAPK1SMN1; SMN2RAB9A | |
| Biphenyl SCHEMBL28098924 | 0.59 | ALDH1A1 (0.90) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 | |
| SCHEMBL31091243 | 0.59 | CYP2A6 (0.56) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 | |
| Biphenyl SCHEMBL23211153 | 0.58 | ALDH1A1 (0.69) | BACE1ALDH1A1HPGDHSD17B10BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | claimed |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | claimed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | claimed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | claimed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP1, MMP2, TNF | BACE1 220/4885ALDH1A1 151/4885HPGD 66/4885 |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | BACE1 345/4885ALDH1A1 281/4885HPGD 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.